PT2979700T - Agente antitumoral que inclui cloridrato de irinotecano hidratado em dose baixa - Google Patents
Agente antitumoral que inclui cloridrato de irinotecano hidratado em dose baixaInfo
- Publication number
- PT2979700T PT2979700T PT14773638T PT14773638T PT2979700T PT 2979700 T PT2979700 T PT 2979700T PT 14773638 T PT14773638 T PT 14773638T PT 14773638 T PT14773638 T PT 14773638T PT 2979700 T PT2979700 T PT 2979700T
- Authority
- PT
- Portugal
- Prior art keywords
- low dose
- antitumor agent
- including low
- agent including
- hydrochloride hydrate
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 title 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013066074 | 2013-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2979700T true PT2979700T (pt) | 2018-12-27 |
Family
ID=51624406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT14773638T PT2979700T (pt) | 2013-03-27 | 2014-03-27 | Agente antitumoral que inclui cloridrato de irinotecano hidratado em dose baixa |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9616081B2 (pt) |
| EP (1) | EP2979700B1 (pt) |
| JP (1) | JP6002835B2 (pt) |
| KR (1) | KR101848131B1 (pt) |
| AU (1) | AU2014245147B2 (pt) |
| CY (1) | CY1120990T1 (pt) |
| DK (1) | DK2979700T3 (pt) |
| ES (1) | ES2702911T3 (pt) |
| HR (1) | HRP20182145T1 (pt) |
| HU (1) | HUE041687T2 (pt) |
| LT (1) | LT2979700T (pt) |
| PL (1) | PL2979700T3 (pt) |
| PT (1) | PT2979700T (pt) |
| RS (1) | RS58067B1 (pt) |
| RU (1) | RU2668125C2 (pt) |
| SI (1) | SI2979700T1 (pt) |
| SM (1) | SMT201800677T1 (pt) |
| TR (1) | TR201819576T4 (pt) |
| TW (1) | TWI641374B (pt) |
| UA (1) | UA117581C2 (pt) |
| WO (1) | WO2014157444A1 (pt) |
| ZA (1) | ZA201507444B (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| RS60958B1 (sr) | 2013-03-27 | 2020-11-30 | Taiho Pharmaceutical Co Ltd | Antitumorski agens koji uključuje irinotekan hidrohlorid hidrat |
| PT3042669T (pt) * | 2013-09-06 | 2023-06-15 | Taiho Pharmaceutical Co Ltd | Agente antitumoral e potencializador de efeito antitumoral |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| KR20180037210A (ko) | 2015-08-20 | 2018-04-11 | 입센 바이오팜 리미티드 | 암 치료를 위한 리포좀 이리노테칸 및 parp 저해제를 이용하는 조합요법 |
| ES2826826T3 (es) | 2015-08-21 | 2021-05-19 | Ipsen Biopharm Ltd | Combinación farmacéutica que comprende irinotecán liposómico, oxaliplatino, 5-fluorouracilo y leucovorina para el tratamiento del cáncer pancreático metastático |
| JP2019533684A (ja) | 2016-11-02 | 2019-11-21 | イプセン バイオファーム リミティド | リポソームイリノテカン、オキサリプラチン、５−フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| JP3088757B2 (ja) | 1995-03-29 | 2000-09-18 | 大鵬薬品工業株式会社 | ウラシル誘導体並びにそれを含有する抗腫瘍効果増強剤及び抗腫瘍剤 |
| MX2007003314A (es) * | 2004-09-22 | 2007-08-06 | Pfizer | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas. |
| PL1839662T3 (pl) * | 2005-01-19 | 2010-08-31 | Zeria Pharm Co Ltd | Środek przeciwnowotworowy |
| RU2394581C2 (ru) * | 2005-01-26 | 2010-07-20 | Тайхо Фармасьютикал Ко., Лтд. | ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ |
| US7799783B2 (en) | 2005-01-26 | 2010-09-21 | Taiho Pharmaceutical Co., Ltd. | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| GB0506708D0 (en) * | 2005-04-01 | 2005-05-11 | Queen Mary & Westfield College | Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions |
| GR20060100144A (el) * | 2006-03-03 | 2007-10-17 | Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene | |
| KR101435228B1 (ko) | 2006-07-14 | 2014-08-28 | 디에스엠 아이피 어셋츠 비.브이. | 조성물, 및 염증성 질환의 치료, 병용-치료 또는 예방을 위한 이의 용도 |
| JP2011157298A (ja) | 2010-02-01 | 2011-08-18 | Aska Pharmaceutical Co Ltd | 胃潰瘍治療剤 |
-
2014
- 2014-03-27 JP JP2015508649A patent/JP6002835B2/ja active Active
- 2014-03-27 PT PT14773638T patent/PT2979700T/pt unknown
- 2014-03-27 RS RS20181521A patent/RS58067B1/sr unknown
- 2014-03-27 TR TR2018/19576T patent/TR201819576T4/tr unknown
- 2014-03-27 AU AU2014245147A patent/AU2014245147B2/en active Active
- 2014-03-27 EP EP14773638.3A patent/EP2979700B1/en active Active
- 2014-03-27 US US14/779,759 patent/US9616081B2/en active Active
- 2014-03-27 HU HUE14773638A patent/HUE041687T2/hu unknown
- 2014-03-27 RU RU2015145997A patent/RU2668125C2/ru active
- 2014-03-27 KR KR1020157026552A patent/KR101848131B1/ko active IP Right Grant
- 2014-03-27 WO PCT/JP2014/058733 patent/WO2014157444A1/ja active Application Filing
- 2014-03-27 PL PL14773638T patent/PL2979700T3/pl unknown
- 2014-03-27 DK DK14773638.3T patent/DK2979700T3/en active
- 2014-03-27 UA UAA201510465A patent/UA117581C2/uk unknown
- 2014-03-27 SI SI201430982T patent/SI2979700T1/sl unknown
- 2014-03-27 LT LTEP14773638.3T patent/LT2979700T/lt unknown
- 2014-03-27 ES ES14773638T patent/ES2702911T3/es active Active
- 2014-03-27 TW TW103111512A patent/TWI641374B/zh active
- 2014-03-27 SM SM20180677T patent/SMT201800677T1/it unknown
-
2015
- 2015-10-07 ZA ZA2015/07444A patent/ZA201507444B/en unknown
-
2018
- 2018-12-18 CY CY181101357T patent/CY1120990T1/el unknown
- 2018-12-18 HR HRP20182145TT patent/HRP20182145T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015145997A (ru) | 2017-05-04 |
| US20160082031A1 (en) | 2016-03-24 |
| EP2979700A1 (en) | 2016-02-03 |
| TR201819576T4 (tr) | 2019-01-21 |
| TWI641374B (zh) | 2018-11-21 |
| EP2979700B1 (en) | 2018-09-26 |
| DK2979700T3 (en) | 2019-01-21 |
| KR101848131B1 (ko) | 2018-04-11 |
| CY1120990T1 (el) | 2019-12-11 |
| RS58067B1 (sr) | 2019-02-28 |
| SMT201800677T1 (it) | 2019-01-11 |
| TW201513864A (zh) | 2015-04-16 |
| WO2014157444A1 (ja) | 2014-10-02 |
| AU2014245147A1 (en) | 2015-10-15 |
| RU2668125C2 (ru) | 2018-09-26 |
| UA117581C2 (uk) | 2018-08-27 |
| HUE041687T2 (hu) | 2019-05-28 |
| JP6002835B2 (ja) | 2016-10-05 |
| US9616081B2 (en) | 2017-04-11 |
| HRP20182145T1 (hr) | 2019-03-08 |
| ES2702911T3 (es) | 2019-03-06 |
| PL2979700T3 (pl) | 2019-03-29 |
| SI2979700T1 (sl) | 2019-01-31 |
| JPWO2014157444A1 (ja) | 2017-02-16 |
| EP2979700A4 (en) | 2016-11-23 |
| ZA201507444B (en) | 2017-01-25 |
| LT2979700T (lt) | 2018-12-27 |
| KR20150136074A (ko) | 2015-12-04 |
| AU2014245147B2 (en) | 2017-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1221672A1 (zh) | 鼻腔給藥 | |
| IL245211A0 (en) | an inhaler for the medicine | |
| HRP20182145T1 (hr) | Antitumorni agens koji uključuje irinotekan hidroklorid hidrat u niskoj dozi | |
| IL246045B (en) | Inhalable drugs | |
| IL245157A0 (en) | Antitumor factor | |
| ZA201603463B (en) | An inhalable medicament | |
| ZA201507442B (en) | Antitumor agent including irinotecan hydrochloride hydrate | |
| IL245760A0 (en) | Inhalation medicine | |
| HK1219662A1 (zh) | 血脂異常症治療劑 | |
| EP3037100A4 (en) | MEANS TO PREVENT MUSCLE ATROPHY | |
| GB201320786D0 (en) | Medicament |